<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01885910</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-000508</org_study_id>
    <nct_id>NCT01885910</nct_id>
  </id_info>
  <brief_title>Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel</brief_title>
  <official_title>Use of Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derm Research, PLLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>WFH MEDICAL, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Derm Research, PLLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will explore if continuation of treatment of treatment with Aczone 5% gel
      following combination treatment with with doxycycline and Aczone 5% gel can maintain
      therapeutic response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-center, open-label pilot study. The study is apprised of 7 study visits:
      Baseline and Weeks 4, 8, 12, 16, 20 and 24. All subjects will receive Aczone 5% gel BID and
      doxycycline 100mg by mouth once daily at Baseline. Those subjects achieving treatment
      response (i.e., IGA of 0, 1 or 2) at Week 12 will continue treatment with Aczone 5% gel BID
      at Week 12. Subjects not achieving treatment response will discontinue study participation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Remained Responders at Week 24</measure>
    <time_frame>Assessed every 4 weeks, reported at Week 24</time_frame>
    <description>At week 12 responder had an IGA &lt;3 on a 6-point scale ranging from 0 (clear) to 5 (very severe) and at Week 24 this response was maintained</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and Non-inflammatory Lesion Counts</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Responders at Week 16 and 20</measure>
    <time_frame>Assessed every 4 weeks, reported at weeks 16 and 20</time_frame>
    <description>Responders is the percentage of participants who have an IGA &lt;3 at Week 16 and 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nodule Counts</measure>
    <time_frame>every four weeks</time_frame>
    <description>number of nodules counted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema</measure>
    <time_frame>every 4 weeks</time_frame>
    <description>the erythema severity scale ranges from 0 to 4 with 0 being no erythema and 4 being most extreme erythema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dryness</measure>
    <time_frame>every 4 weeks</time_frame>
    <description>the dryness severity scale ranges from 0 to 4 with 0 being no dryness and 4 being most extreme dryness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peeling</measure>
    <time_frame>every four weeks</time_frame>
    <description>the peeling severity scale ranges from 0 to 4 with 0 being no peeling and 4 being most extreme peeling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oiliness</measure>
    <time_frame>every 4 weeks</time_frame>
    <description>the oiliness severity scale ranges from 0 to 10 with 0 being no oiliness and 10 being most extreme oiliness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritis</measure>
    <time_frame>every 4 weeks</time_frame>
    <description>the pruritis severity scale ranges from 0 to 5 with 0 being no pruritis and 5 being the most extreme pruritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burning</measure>
    <time_frame>every 4 weeks</time_frame>
    <description>the burning severity scale ranges from 0 to 10 with 0 being no burning and 10 being most extreme burning</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>doxy + aczone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will start treatment with doxycycline 100mg once daily and Aczone 5% gel applied to the face twice daily and those who improve significantly are continued on Aczone gel alone to see if it can maintain therapeutic response</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 100mg</intervention_name>
    <description>Doxycycline 100mg by mouth once daily</description>
    <arm_group_label>doxy + aczone</arm_group_label>
    <other_name>Vibramycin, Oracea, Adoxa, Atridox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aczone 5% gel</intervention_name>
    <description>Aczone 5% gel twice daily</description>
    <arm_group_label>doxy + aczone</arm_group_label>
    <other_name>Dapsone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient, male or female subjects of any race, age 12 or older. Female subjects of
             childbearing potential must have a negative urine pregnancy test result at Baseline
             and practice a reliable method of contraception throughout the study;

          -  Facial acne vulgaris characterized by the following:

        IGA Score &gt;3 10-50 facial inflammatory lesions (papules,pustules) 10-100 facial
        non-inflammatory lesions (open/closed comedones)

          -  Able to understand and comply with the requirements of the study and sign Informed
             Consent/HIPAA Authorization forms

        Exclusion Criteria:

          -  Female subjects who are pregnant (positive urine pregnancy test), breast feeding, or
             who are of childbearing potential and not practicing a reliable method of birth
             control.

          -  Allergy/sensitivity to any component of the test treatment (Section 5.2), lincomycin,
             tetracyclines, or sulfites.

          -  Subjects who have not complied with the proper wash-out periods for prohibited
             medications/procedures (Supplement 1)&gt;

          -  History of clinically significant anemia or hemolysis.

          -  History of enteritis (regional enteritis, ulcerative colitis, pseudomembranous
             colitis, or antibiotic-associated colitis).

          -  Skin disease/disorder that might interfere with the diagnosis or evaluation of acne
             vulgaris

          -  Evidence of recent alcohol or drug abuse

          -  Medical condition that, in the opinion of the Investigator, contraindicates the
             subject's participation in the clinical study

          -  History of poor cooperation, non-compliance with medical treatment or unreliability

          -  Participation in an investigational drug study within 30 days of the baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon H Kircik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DermResearch, PLLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2013</study_first_submitted>
  <study_first_submitted_qc>June 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2013</study_first_posted>
  <results_first_submitted>October 7, 2014</results_first_submitted>
  <results_first_submitted_qc>February 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2015</results_first_posted>
  <last_update_submitted>February 26, 2015</last_update_submitted>
  <last_update_submitted_qc>February 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment at 2 sites for subjects at least 12 years of age with moderate to severe acne vulgaris began June 2013 and ended December 2013</recruitment_details>
      <pre_assignment_details>Any subject might be excluded who is not at least 12 years of age, who does not have moderate to severe acne vulgaris based upon IGA score and lesion counts, who has not completed the proper washout of specified medications, or who has been in another investigational study 30 days prior</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Doxy + Aczone</title>
          <description>Subjects will start treatment with doxycycline 100mg once daily and Aczone 5% gel applied to the face twice daily
Doxycycline 100mg and Aczone 5% gel: Subject is to take Doxycycline 100mg by mouth once daily and apply Aczone 5% gel to their face twice daily for 12 weeks; those subjects achieving treatment response will stop Doxycycline and continue applying Aczone 5% gel twice daily for 12 more weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>subjects at least 12 years of age who have moderate to severe acne vulgaris</population>
      <group_list>
        <group group_id="B1">
          <title>Aczone/Doxy</title>
          <description>subjects will take doxy 100mg daily and apply aczone 5% gel to the face twice daily for 12 weeks after which if their acne has improved they will continue on maintenance therapy of aczone gel for another 12 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Remained Responders at Week 24</title>
        <description>At week 12 responder had an IGA &lt;3 on a 6-point scale ranging from 0 (clear) to 5 (very severe) and at Week 24 this response was maintained</description>
        <time_frame>Assessed every 4 weeks, reported at Week 24</time_frame>
        <population>only participants who were not lost to follow-up or did not withdraw consent were included in the final analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Aczone/Doxy</title>
            <description>subjects will take doxy 100mg daily and apply aczone 5% gel to the face twice daily for 12 weeks after which if their acne has improved they will continue on maintenance therapy of aczone gel for another 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Remained Responders at Week 24</title>
          <description>At week 12 responder had an IGA &lt;3 on a 6-point scale ranging from 0 (clear) to 5 (very severe) and at Week 24 this response was maintained</description>
          <population>only participants who were not lost to follow-up or did not withdraw consent were included in the final analysis</population>
          <units>percentage of particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory and Non-inflammatory Lesion Counts</title>
        <time_frame>Every 4 weeks</time_frame>
        <population>participants with data</population>
        <group_list>
          <group group_id="O1">
            <title>Aczone/Doxy - Inflammatory</title>
            <description>inflammatory lesion counts during treatment with aczone 5% and doxycycline 100mg</description>
          </group>
          <group group_id="O2">
            <title>Aczone/Doxy - Non Inflammatory</title>
            <description>non inflammatory lesion counts during treatment with aczone 5% and doxy 100mg</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory and Non-inflammatory Lesion Counts</title>
          <population>participants with data</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="14.6"/>
                    <measurement group_id="O2" value="38.3" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16 (n=23,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="4.9"/>
                    <measurement group_id="O2" value="10.0" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 20 (n=23,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="9.2"/>
                    <measurement group_id="O2" value="8.3" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24 (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="9.1"/>
                    <measurement group_id="O2" value="6.6" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Are Responders at Week 16 and 20</title>
        <description>Responders is the percentage of participants who have an IGA &lt;3 at Week 16 and 20</description>
        <time_frame>Assessed every 4 weeks, reported at weeks 16 and 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aczone/Doxy</title>
            <description>subjects will take doxy 100mg daily and apply aczone 5% gel to the face twice daily for 12 weeks after which if their acne has improved they will continue on maintenance therapy of aczone gel for another 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Responders at Week 16 and 20</title>
          <description>Responders is the percentage of participants who have an IGA &lt;3 at Week 16 and 20</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>responders at week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>responders at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nodule Counts</title>
        <description>number of nodules counted</description>
        <time_frame>every four weeks</time_frame>
        <population>participants with data</population>
        <group_list>
          <group group_id="O1">
            <title>Aczone/Doxy</title>
            <description>subjects will take doxy 100mg daily and apply aczone 5% gel to the face twice daily for 12 weeks after which if their acne has improved they will continue on maintenance therapy of aczone gel for another 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Nodule Counts</title>
          <description>number of nodules counted</description>
          <population>participants with data</population>
          <units>nodules</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema</title>
        <description>the erythema severity scale ranges from 0 to 4 with 0 being no erythema and 4 being most extreme erythema</description>
        <time_frame>every 4 weeks</time_frame>
        <population>participants with data</population>
        <group_list>
          <group group_id="O1">
            <title>Aczone/Doxy</title>
            <description>subjects will take doxy 100mg daily and apply aczone 5% gel to the face twice daily for 12 weeks after which if their acne has improved they will continue on maintenance therapy of aczone gel for another 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema</title>
          <description>the erythema severity scale ranges from 0 to 4 with 0 being no erythema and 4 being most extreme erythema</description>
          <population>participants with data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 20 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24 (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dryness</title>
        <description>the dryness severity scale ranges from 0 to 4 with 0 being no dryness and 4 being most extreme dryness</description>
        <time_frame>every 4 weeks</time_frame>
        <population>participants with data</population>
        <group_list>
          <group group_id="O1">
            <title>Aczone/Doxy</title>
            <description>subjects will take doxy 100mg daily and apply aczone 5% gel to the face twice daily for 12 weeks after which if their acne has improved they will continue on maintenance therapy of aczone gel for another 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Dryness</title>
          <description>the dryness severity scale ranges from 0 to 4 with 0 being no dryness and 4 being most extreme dryness</description>
          <population>participants with data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 20 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24 (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peeling</title>
        <description>the peeling severity scale ranges from 0 to 4 with 0 being no peeling and 4 being most extreme peeling</description>
        <time_frame>every four weeks</time_frame>
        <population>participants with data</population>
        <group_list>
          <group group_id="O1">
            <title>Aczone/Doxy</title>
            <description>subjects will take doxy 100mg daily and apply aczone 5% gel to the face twice daily for 12 weeks after which if their acne has improved they will continue on maintenance therapy of aczone gel for another 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Peeling</title>
          <description>the peeling severity scale ranges from 0 to 4 with 0 being no peeling and 4 being most extreme peeling</description>
          <population>participants with data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 20 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24 (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oiliness</title>
        <description>the oiliness severity scale ranges from 0 to 10 with 0 being no oiliness and 10 being most extreme oiliness</description>
        <time_frame>every 4 weeks</time_frame>
        <population>participants with data</population>
        <group_list>
          <group group_id="O1">
            <title>Aczone/Doxy</title>
            <description>subjects will take doxy 100mg daily and apply aczone 5% gel to the face twice daily for 12 weeks after which if their acne has improved they will continue on maintenance therapy of aczone gel for another 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Oiliness</title>
          <description>the oiliness severity scale ranges from 0 to 10 with 0 being no oiliness and 10 being most extreme oiliness</description>
          <population>participants with data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 20 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24 (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pruritis</title>
        <description>the pruritis severity scale ranges from 0 to 5 with 0 being no pruritis and 5 being the most extreme pruritis</description>
        <time_frame>every 4 weeks</time_frame>
        <population>participants with data</population>
        <group_list>
          <group group_id="O1">
            <title>Aczone/Doxy</title>
            <description>subjects will take doxy 100mg daily and apply aczone 5% gel to the face twice daily for 12 weeks after which if their acne has improved they will continue on maintenance therapy of aczone gel for another 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pruritis</title>
          <description>the pruritis severity scale ranges from 0 to 5 with 0 being no pruritis and 5 being the most extreme pruritis</description>
          <population>participants with data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 20 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24 (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Burning</title>
        <description>the burning severity scale ranges from 0 to 10 with 0 being no burning and 10 being most extreme burning</description>
        <time_frame>every 4 weeks</time_frame>
        <population>participants with data</population>
        <group_list>
          <group group_id="O1">
            <title>Aczone/Doxy</title>
            <description>subjects will take doxy 100mg daily and apply aczone 5% gel to the face twice daily for 12 weeks after which if their acne has improved they will continue on maintenance therapy of aczone gel for another 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Burning</title>
          <description>the burning severity scale ranges from 0 to 10 with 0 being no burning and 10 being most extreme burning</description>
          <population>participants with data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 20 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24 (N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Subjects were interviewed regarding changes in their health and the severity of pruritis and burning at each study visit; each subject was graded at each study visit regarding their current severity of erythema, dryness, peeling and oiliness on a 5-point scale.</desc>
      <group_list>
        <group group_id="E1">
          <title>Doxy + Aczone</title>
          <description>Subjects will start treatment with doxycycline 100mg once daily and Aczone 5% gel applied to the face twice daily
Doxycycline 100mg and Aczone 5% gel: Subject is to take Doxycycline 100mg by mouth once daily and apply Aczone 5% gel to their face twice daily for 12 weeks; those subjects achieving treatment response will stop Doxycycline and continue applying Aczone 5% gel twice daily for 12 more weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>resolved, no residual effects</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>resolved, no residual effects</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>burning</sub_title>
                <description>not resolved, f/u deemed unnecessary</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>pruritis</sub_title>
                <description>resolved, no residual effects</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>resolved, no residual effects</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Leon Kircik</name_or_title>
      <organization>DermResearch, PLLC</organization>
      <phone>502-451-9000</phone>
      <email>wedoderm@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

